Status:
UNKNOWN
Substudy of CADRE: for People With Extreme Phenotype: BIOCADRE
Lead Sponsor:
Cardiologie et Développement
Collaborating Sponsors:
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Sickle Cell Disease
Eligibility:
All Genders
10+ years
Brief Summary
BIOCADRE is a CADRE substudy and aims to characterize more precisely the sickle cell patients with extreme phenotype.
Detailed Description
Sickle cell disease (SCD) is the most frequent monogenic disease in the world, due to a unique mutation on the β-globin gene. Most affected individuals live in sub-Saharan Africa, yet, the natural his...
Eligibility Criteria
Inclusion
- sickle cell patients with extreme phenotypes: SS-hemoglobin
Exclusion
- transfusion in the previous 2 months
- vaso-occlusive crisis in the previous 15 days
- infection in the previous 8 days
Key Trial Info
Start Date :
May 15 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2019
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03352986
Start Date
May 15 2017
End Date
December 1 2019
Last Update
November 24 2017
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de Recherches er de Lutte contre la Drépanocytose
Bamako, Mali
2
Centre National de Transfusion Sanguine
Dakar, Senegal